Belzutifan · Welireg
Small molecule
Also known as MK-6482
Evidence outlook
Approved: Renal Cell Carcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (1)
- Pheochromocytoma or Paraganglioma WELIREG is indicated for the treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (1)
What this study did
Competitive landscape
Other HIF-2alpha drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Renal Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Belzutifan (Welireg): this drug | Approved | Small molecule | HIF-2alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | not yet graded | No reviewed efficacy summary in this indication | |
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Avelumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Axitinib | Approved | Small molecule | VEGFR1/2/3 | Partial signal | NCT02684006: Primaries in PD-L1-positive patients, avelumab + axitinib vs sunitinib: PFS (BICR) median 13.8 vs 7.2 months, hazard ratio 0.61 (95% CI 0.475 to 0.790), p=0.0001, met; OS median 43.2 vs 36.2 months, hazard ratio 0.86 (95% CI 0.701 to 1.057), p=0.1509, not significant (CT.gov posted results). | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | No reviewed efficacy summary in this indication | |
| Everolimus | Approved | Small molecule | mTOR kinase, mTOR (mTORC1) (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT01668784: Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Nivolumab 25 months | Everolimus 19.55 months (95% CI 17.64 to 23.06) | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pazopanib (Votrient) | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | Reliable signal | Featured results are non-efficacy only in this race | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02811861: Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Lenvatinib 18 mg Plus Everolimus 5 mg 14.7 months (95% CI 11.1 to 16.7) | Lenvatinib 20 mg Plus Pembrolizumab 200 mg 23.9 months (95% CI 20.8 to 27.7) | Sunitinib 50 mg 9.2 months (95% CI 6 to 11) NCT04704219: Objective Response Rate (ORR) (Up to approximately 47 months): Pembrolizumab + Lenvatinib 50.6 Percentage of participants (95% CI 42.6 to 58.7) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Zirabev (bevacizumab-Bvzr) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Casdatifan | Phase 3(overall) | Small molecule | HIF-2alpha | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Durvalumab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Fruquintinib (Fruzaqla / Elunate) | Phase 3 | Small molecule | VEGFR1/2/3 | not yet graded | No reviewed efficacy summary in this indication | |
| Savolitinib (Orpathys) | Phase 3 | Small molecule | MET | not yet graded | No reviewed efficacy summary in this indication | |
| Zanzalintinib | Phase 3 | Small molecule | VEGFR2; MET; AXL; MER; TYRO3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ciforadenant | Phase 1/2 | Small molecule | adenosine A2A | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(22 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Welireg (Belzutifan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.